ClinicalTrials.gg
RecruitingNCT06705738MeDi-SUPOLUpdated Oct 7, 2026

The Effect of Combination of Mediterranean Diet and Oleocanthal in Patients With Mild Cognitive Impairment

An interventional study of SUPOL and Dietary Pattern: MeDi in Mild Cognitive Impairment, sponsored by Aristotle University Of Thessaloniki. Recruiting at 2 sites in Greece. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Aristotle University Of Thessaloniki · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 7, 2026Now RecruitingStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki — 4 open to participants now, 5 under way, none of them phase 3. Cognitive Dysfunction · Aristotle University Of Thessaloniki.

Planned enrollment
3rd of 10
200 · median 114
Started
2025
with 2 others
No phase
9 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 9th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

4 of the 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki, or all of them as a file.
02

Study summary

BACKGROUND: Mild cognitive impairment (MCI) constitutes a form of preclinical dementia and characterizes a cognitive decline that exceeds what is expected for one's age and education status, but at the same time does not fulfill the criteria for dementia. MCI is considered a prodromal stage of Alzheimer's disease (AD) and the progression to this neurodegenerative disease, renders the patients heavily dependent on their relatives and the society, which creates a huge psychological and financial burden, since no effective treatment exists for MCI and AD to this day. Mediterranean diet (MeDi) displays beneficial effects on the cognitive function of both healthy individuals and cognitive impaired patients. High Phenolic Early Harvest Extra Virgin Olive Oil (HP-EH-EVOO) is a natural product that contains high concentrations of the substance Oleocanthal (OLC), while at the same time it has been shown to exert beneficial properties on the cognitive function of cognitive impaired individuals, as well as on the slowing down of the decline of cognitive function.

AIM: The main hypothesis that will be evaluated is whether the combined approach of the MeDi pattern and the concurrent intervention with the administration in a capsule form of the supplement containing olive oil polyphenols with the main substance being Oleocanthal (SUPOL), could constitute a considerable strategy of management of MCI patients.

Study Type: Investigational Study Design, Allocantion: Randomized Intervention Model, Parallel Assignment Masking: Double Blind (Subject, Outcome Assessor - Investigator) on Supplement, Primary Purpose: Prevention.

Read the detailed description

OBJECTIVE OF THE TRIAL: To evaluate the efficacy of the combined approach of the MeDi pattern and the concurrent SUPOL compared to the MeDi diet pattern in combination with placebo on the change in cognition and function in subjects with MCI.

STUDY DESIGN: The study is designed as a 2x2 quasi-factorial design, which combines the characteristics of a prospective cohort study regarding dietary patterns and a randomized, placebo-controlled, 4-parallel-group clinical trial, double-blinded with respect to the dietary supplement.

PARTICIPANTS: Participants upon enrollment will be classified into two distinct cohorts based on their level of adherence to the MeDi (high and moderate adherence). The recruitment of N=200 participants with MCI is planned, who will initially be stratified into two strata: high adherence to the MeDi (n=100) and moderate adherence to the MeDi (n=100). Subsequently, participants within each cohort will be randomized in a 1:1 ratio to receive either SUPOL or placebo, creating 4 groups of n=50 individuals:

  • Group 1: High adherence to the MeDi and SUPOL intake
  • Group 2: High adherence to the MeDi and placebo intake
  • Group 3: Moderate adherence to the MeDi and SUPOL intake
  • Group 4: Moderate adherence to the MeDi and placebo intake.

The assessment and grading of participants' adherence to the MeDi at baseline will be performed using the MedDietScore. Participants will be classified as follows:

  • Moderate adherence to the MeDi: MedDietScore 21-35
  • High adherence to the MeDi: MedDietScore 36-55
  • Patients with low adherence to the MeDi (MedDietScore 0-20) will be excluded from the study to ensure the homogeneity of the comparison groups.

DURATION: The duration of the intervention will be 12 months, while the neuropsychological assessment and laboratory testing will be performed at baseline, after the end of the intervention at 12 months and at 18 months (6 months after the completion of the intervention). The total study duration will be 18 months.

LOCATION: The study will be conducted in Thessaloniki and will recruit patients having diagnosed with MCI from the outpatient clinic 1st Neurological Clinic of the General University Hospital "AHEPA" (AHEPA) and the Greek Association of Alzheimer's Disease and Related Disorders (Alzheimer Hellas).

SCREENING - RANDOMIZATION - BASELINE (Visit 1): Patient eligibility will be determined during Visit 1. A protocol eligibility form will be completed for each patient and reviewed by the Principal Investigator (PI) approval prior to participation in the study. If eligibility is reached, baseline assessments, as well as randomization for group allocation will take place.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • Mediterranean diet
  • Western type diet
  • Olive oil polyphenols
  • Oleocanthal
  • Mild cognitive impairment
  • Alzheimer disease
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in this study only if all the following criteria apply:

  • Men or women,
  • 60 to 85 years of age inclusive, at the time of signing the form (ICF).
  • (MMSE) score of 26-28 at Screening (Visit 1).
  • Montreal Cognitive Assessment (MoCA) score of 20-26 at Visit 1.
  • MRI scan evaluation at Visit 1.
  • CSF biomarkers evaluation at Visit 1.
  • Adequate knowledge and understanding of the Greek language, as well as adequate literacy, vision and hearing for neuropsychological testing in the opinion of the Principal Investigator (PI) at the time of screening.
  • They are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Medical conditions

  • Significant neurological diseases that affect the central nervous system other than MCI, that may affect cognition ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease (PD), Multiple sclerosis (MS), multiple concussions, epilepsy or recurrent seizures.
  • Ongoing serious or unstable illnesses, including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, psychiatric, immunologic, hema-tologic diseases and other conditions that, in the PI's opinion, could interfere with the analyses in this study or has a of less than 24 months.
  • History of cancer within the last 5 years, with exception of non- basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, other cancers with low risk of recurrence or spread.
  • Participants with any current primary psychiatric diagnosis, if in the judgement of the PI for the psychiatric disorder or symptom is likely to confound interpretation of the combined approach effect, affect cognitive assessment or affect the partici-pant's ability to complete the study. Participants with history of schizophrenia or other chronic psychosis are excluded.
  • In the judgement of the PI, participants are actively suicidal and therefore deemed to be at significant risk of suicide.
  • History of alcohol or drug abuse disorder (except tobacco use disorder) within 2 years before Visit 1.
  • History of multiple or severe drug allergies, significant atopy or severe post-treatment reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis and/or exfoliative dermatitis).
  • Patient has undergone surgical operation of the gastrointestinal tract (GI tract) that led to removal of a functional part of the GI tract, length shortage of the GI tract and change of the GI tract morphology.

Imaging, Vital Signs, Laboratory Tests and Physical Examinations

  • Any clinically important abnormality at Visit 1, as determined by the PI, in physical or neurological examination, vital signs or clinical laboratory test results, that could be detrimental to the participant, could compromise the study or show evidence of other etiologies for MCI.
  • MRI which shows evidence of significant abnormality that would suggest another potential etiology for MCI or a clinically significant finding that may impact the participant's ability to safely participate in the study.
  • Have any for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.
  • Poor venous access.
  • Evidence of a relevant neurological disorder other than MCI at Visit 1, including but not limited to PD, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, MS, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, , learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits.
  • Evidence of a clinically relevant or unstable psychiatric disorder, based on Diag-nostic and Statistical Manual of Mental Disorders Fifth Edition () criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or in the case that depression is controlled with treatment can be included in the trial per inves-tigator's judgement.
  • Imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicide Severity Rating Scale (C-SSRS) or of harm to self or others in the opinion of the PI.

Prior or Concomitant Therapy

  • Known allergies to EVOO, OLC, Oleacein (OLE), Oleuropein Aglycon (OLA), Ligstroside Aglycon (LIG), Tyrosol (TYR), Hydroxytyrosol (HT) or any other components of the formulation.
  • Contraindications in following a MeDi or Western diet pattern and are not willing to adhere to the abovementioned nutritional lifestyles.
  • Consumption of high-dose nutritional supplements.
  • Long-term antibiotic therapy.
  • Regular consumption of probiotics.
  • Regular intake of enriched commercial probiotic foods.

Prior or Concurrent Clinical Study Experience

  • Currently enrolled in any other interventional clinical trial involving an medicinal product (IMP) or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Participated, within the last 30 days in a clinical trial involving an IMP. If the precious IMP is scientifically or medically incompatible with this study and has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed prior to Visit 1 (participation in observational studies may be permitted upon review or the observational study protocol and approved by the PI).
  • Previously completed or withdrawn from this study or received SUPOL in any prior investigational study. (This exclusion criterion does not apply to participants who are allowed to rescreen before randomization in this study).

Other exclusions

  • Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
  • Currently OMPHAX SA (OMPHAX) employees or employees of third-party organizations (TPOs) involved in study which requires exclusion of their employees or have relatives or partners who are OMPHAX employees or are employees of TPOs involved in a study which requires exclusion of their employees.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    1st group

    50 participants with high adherence to the MeDi pattern will receive SUPOL for 12 months.

    Dietary Supplement: SUPOL · Other: Dietary Pattern: MeDi

  • Placebo comparator
    2nd group

    50 participants with high adherence to the MeDi pattern will receive placebo for 12 months.

    Other: Dietary Pattern: MeDi

  • Active comparator
    3rd group

    50 participants with medium adherence to the MeDi pattern will receive SUPOL for 12 months.

    Dietary Supplement: SUPOL

  • No intervention
    4th group

    50 participants with medium adherence to the MeDi pattern will receive placebo for 12 months.

Interventions

  • Dietary supplementSUPOL

    Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.

  • OtherDietary Pattern: MeDi

    High Adherance to MeDi pattern to be followed for 12 months.

06

What researchers measure

Primary outcomes

  1. ADAS-Cog - Measurement to Assess the Severity of Cognitive Impairment

    Alzheimer's Disease Assessment Scale - Cognitive Subscale - 13 (ADAS-Cog-13) neuropsychological assessment scale scores ranges from 0 to 85, with greater scores showing a more significant cognitive impairment

    Time frame: Baseline (Day 1) to 12 months

  2. MMSE - Measurement to Assess and Evaluate Cogntive Function

    Mini-Mental State Examination (MMSE) score ranges range from 0 to 30 and individuals will lower MMSE scores show greater cognitive impairment

    Time frame: Baseline (Day 1) to 12 months

Secondary outcomes

  1. MoCA - Measurement to Assess Cognitive Abilities

    Montreal Cognitive Assessment (MoCA) total score ranges from 0 to 30 and lower scores indicating greater impairment

    Time frame: Baseline (Day 1) to 12 months

  2. ADCS-ADL-MCI - Measurement to Assess and Evaluate the Performance in Different Activities of Daily Living

    Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) MCI scale score ranges from 0 to 53, with poorer scores representing a more significant cognitive impairment

    Time frame: Baseline (Day 1) to 12 months

  3. CDR-SB - Measurement to Assess the Severity of the Disease and the Progression of the Disease

    Clinical Dementia Rating Sum of Boxes (CDR-SB) total score ranges from 0 to 18, with greater scores corresponding to more significant impairment

    Time frame: Baseline (Day 1) to 12 months

  4. CDR - Measurement of Time to Progression to Dementia

    Clinical Dementia Rating (CDR) global score ranges from 0 to 3, with the higher score corrisponding to severe dementia and the time to progression to dementia will be measured in weeks (unit)

    Time frame: Baseline (Day 1) to 12 months

  5. GDS - Measurement to Identify Depression in the Elderly

    Geriatric Depression Scale (GDS) total score ranges from 0 to 30, with the classification of severity to be: (a) normal 0-9, (b) mild depression 10-19 and (c) severe depression 20-30

    Time frame: Baseline (Day 1) to 12 months

  6. C-SSRS - Measurement to Determine the Potential Risk for Suicide

    "The Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity of Ideation score ranges from 0 to 25, with higher numbers indicating more intense suicidal ideation

    Time frame: Baseline (Day 1) to 12 months

  7. TEAEs - Measurment of Number of Treatment Emergent Adverse Events

    Number of treatment emergent adverse events (TEAEs) are measured in number of events from baseline

    Time frame: Baseline (Day 1) to 12 months

  8. Measurement of Change in the Vital Signs

    Number of participants with change from baseline in blood pressure (measured in mmHg) will be assessed

    Time frame: Baseline (Day 1) to 12 months

  9. Measurement of Change in the Vital Signs

    Number of participants with change in pulse rate (heart beats per minute) will be assessed

    Time frame: Baseline (Day 1) to 12 months

  10. Measurement of Change in Physical Examination

    Number of participants with change from baseline in physical examination will be evaluated

    Time frame: Baseline (Day 1) to 12 months

  11. Measurement of Change in Neurological Examination

    Number of participants with change from baseline on neurological examination will be evaluated

    Time frame: Baseline (Day 1) to 12 months

  12. Measurment of Change in Clinical Laboratory Tests

    Number of participants with change from baseline in biochemical test will be evaluated

    Time frame: Baseline (Day 1) to 12 months

  13. Measurement of Change in Clinical Laboratory Tests

    Number of participants with change from baseline in haematological test wiil be evaluated

    Time frame: Baseline (Day 1) to 12 months

Other outcomes

  1. Measurment of Change in Plasma Aβ1-42

    Change in mean values of beta-amyloid 1-42 protein (Aβ1-42) plasma concentration

    Time frame: Baseline (Day 1) to 12 months

  2. Measurment of Change in Plasma Aβ1-40

    Change in mean values of beta-amyloid 1-40 protein (Aβ1-40) plasma concentration

    Time frame: Baseline (Day 1) to 12 months

  3. Measurement of Change in the Aβ1-42/Aβ1-40 Plasma Ratio

    Change in the Amyloid-β1-42/Amyloid-β1-40 (Aβ1-42/Aβ1-40) ration in plasma levels

    Time frame: Baseline (Day 1) to 12 months

  4. Measurment of Change in Plasma pTau-181

    Change in mean values of phosphorylated Tau-181 protein (pTau-181) plasma concentration

    Time frame: Baseline (Day 1) to 12 months

  5. Measurment of Change in Plasma pTau-217

    Change in mean values of phosphorylated Tau-217 protein (pTau-217) plasma concentration

    Time frame: Baseline (Day 1) to 12 months

  6. Measurment of Change in Plasma GFAP

    Change in mean values of Glial Fibrillary Acidic Protein (GFAP) plasma concentration

    Time frame: Baseline (Day 1) to 12 months

  7. Measurement of Change in Plasma IL-1β

    Change in mean value of Inteleukin-1β (IL-1β) plasma levels

    Time frame: Baseline (Day 1) to 12 months

  8. Measurement of Change in Plasma IL-6

    Change in mean value of Inteleukin-6 (IL-6) plasma levels

    Time frame: Baseline (Day 1) to 12 months

  9. Measurement of Change in Plasma CRP

    Change in mean value of C-Reactive Protein (CRP) plasma levels

    Time frame: Baseline (Day 1) to 12 months

  10. Measurement of Change in Gut Microbiota Composition

    Change in gut microbiome alpha-diversity (α-diversity) and beta-diversity (β-diversity)

    Time frame: Baseline (Day 1) to 12 months

  11. Measurment of Change in Gut Microbiome Metabolites

    Change in the gut microbiome short chain fatty acids (SCFAs) and medium chain fatty acids (MCFAs) concentration

    Time frame: Baseline (Day 1) to 12 months

07

Study locations

1 of 2 sites recruiting
  • "AHEPA" General University Hospital of Thessaloniki
    Thessaloniki, Thessaloniki 54636, Greece
    Not yet recruiting
  • Greek Association of Alzheimer's Disease and Related Disorders
    Thessaloniki, Thessaloniki 54643, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — No plans to share data with other researchers

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2029, 55 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 55 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Nov 2024 → Jan 2025, primary completion Apr 2026 → Sep 2029 and completion Nov 2026 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 26, 2024
StartActual
Jan 31, 2025was Nov 2024
Primary completionEst.
Sep 30, 2029was Apr 2026
CompletionEst.
Nov 30, 2029was Nov 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 7, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Greece)
  • "AHEPA" General University Hospital of Thessaloniki · Thessaloniki, Greece
  • Greek Association of Alzheimer's Disease and Related Disorders · Thessaloniki, Greece
Show 2 removed
  • "AHEPA" General University Hospital of Thessaloniki · Thessaloniki, Greece
  • Greek Association of Alzheimer's Disease and Related Disorders · Thessaloniki, Greece
Oct 7, 2026
Start date
Nov 1, 2024→Jan 31, 2025
Oct 7, 2026
Primary completion
Apr 30, 2026→Sep 30, 2029
Oct 7, 2026
Study completion
Nov 1, 2026→Nov 30, 2029
Oct 7, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionC-SSRS - Measurement to Determine the Potential Risk for Suicide: how it is measured was reworded
Oct 7, 2026
Contact
Study contact now listed: added t•••@gmail.com · •••1156; added p•••@outlook.com.gr · •••7219. See the current contact
Oct 7, 2026
Sponsor
Collaborators added: National and Kapodistrian University of Athens
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Recruiting
    2 sites added, 2 sites removed
    Show 2 added (2 Greece)
    • "AHEPA" General University Hospital of Thessaloniki · Thessaloniki, Greece
    • Greek Association of Alzheimer's Disease and Related Disorders · Thessaloniki, Greece
    Show 2 removed
    • "AHEPA" General University Hospital of Thessaloniki · Thessaloniki, Greece
    • Greek Association of Alzheimer's Disease and Related Disorders · Thessaloniki, Greece
    Start date Nov 1, 2024→Jan 31, 2025
    Primary completion Apr 30, 2026→Sep 30, 2029
    Study completion Nov 1, 2026→Nov 30, 2029
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionC-SSRS - Measurement to Determine the Potential Risk for Suicide: how it is measured was reworded
    Sponsor Collaborators added: National and Kapodistrian University of Athens
    Contact Study contact now listed: added t•••@gmail.com · •••1156; added p•••@outlook.com.gr · •••7219. See the current contact
    + 7 other changes: identifiers, verification date, oversight details, description, design details, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06705738
Collaborators
Greek Alzheimer's Association and Related Disorders, University of Glasgow, World Olive Center for Health, National and Kapodistrian University of Athens
Responsible party
Magda Tsolaki (Emeritus Professor Tsolaki Magdalini, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Nov 26, 2024
Start date
Jan 31, 2025
Primary completion
Sep 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Magdalini Tsolaki, Emeritus Professor
Contact
tsolakim1@gmail.com
0030 23102411 56
Panagiotis-Marios Sotiriadis, Doctoral Candidate
Contact
pm_sotiriadis@outlook.com.gr
0030 6978667219

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion